Drug Profile
Research programme: amyotrophic lateral sclerosis therapies - Aestus/ALS TDI
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Aestus Therapeutics; ALS Therapy Development Institute
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA
- 18 Mar 2010 Early research in Amyotrophic lateral sclerosis in USA (unspecified route)